Lilly-Verve Proxy Filing Reveals Tumult After Departure of FDA’s Marks

Jefferies analysts called the proxy filing, which is a standard disclosure after a merger agreement, “much more intriguing than normal” given the regulatory turmoil it revealed.

Scroll to Top